Magnetic resonance imaging quality and volumes of brain structures from live and postmortem imaging of California sea lions with clinical signs of domoic acid toxicosis
EW Montie(Marine Mammal Center), Frances M. D. Gulland(Marine Mammal Center), Jerome Barakos(Sutter Health), TWK Battey(Eckerd College), E. F. Wheeler(Marine Mammal Center), Nicola Pussini(Marine Mammal Center), K Colegrove(University of California, Davis), Sophie Dennison(Marine Mammal Center)
Cited by 33
Related Papers
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
|Neurology|2009|741
11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study
|The Lancet Neurology|2010|696
Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease
|JAMA Neurology|2021|602
Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis
|The Lancet Neurology|2012|512
Novel symptomatology and changing epidemiology of domoic acid toxicosis in California sea lions ( <i>Zalophus californianus</i> ): an increasing risk to marine mammal health
|Proceedings of the Royal Society B Biological Sciences|2007|207